Leukeran coated tablets 2 mg. №25 vial

Description

Leukeran Description
Leukeran drug is an antineoplastic agent. Possesses a wide spectrum of antitumor activity, to a greater extent acts on lymphoid tissue than on granulocytes. May cause irreversible myelosuppression.

Leukeran Indications for use
Indications for the use of the drug Leukeran are: lymphogranulomatosis (Hodgkin’s disease); malignant lymphomas (including lymphosarcoma); chronic lymphocytic leukemia; Waldenstrom’s macroglobulinemia.

Leukeran Mode of application
Leukeran is usually one of the components of combination therapy, in connection with which, when choosing the doses and the mode of administration of the drug, refer to the special literature. Leikeran is taken orally. The tablets should not be divided into parts.
Hodgkin’s disease. In the form of monotherapy, Leikeran is usually used at a dose of 0.2 mg / kg of body weight / day for 4-8 weeks.
Non-Hodgkin’s lymphomas. In the form of monotherapy, Leikeran is usually used initially at a dose of 0.1-0.2 mg / kg body weight / day for 4-8 weeks; then maintenance therapy is carried out either at a lower daily dose, or in intermittent courses.

Leukeran Side effects
On the part of the hematopoietic system: very often – leukopenia (reversible if the drug is discontinued in a timely manner), thrombocytopenia, lymphopenia, neutropenia, decreased hemoglobin content; extremely rarely – irreversible depression of bone marrow function.
From the gastrointestinal tract: often – nausea, vomiting, diarrhea, ulceration of the oral mucosa; rarely – hepatotoxic effect of toxic-allergic genesis (hepatonecrosis or cirrhosis, cholestasis, jaundice).
From the respiratory system: extremely rarely – interstitial pulmonary fibrosis (with prolonged use of chlorambucil), interstitial pneumonia.
Allergic reactions: sometimes – skin rash; rarely – urticarial rash, angioedema; extremely rarely – exudative erythema multiforme (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome).
From the nervous system: often – convulsions in children with nephrotic syndrome; rarely – local and / or generalized convulsions in children and adults receiving chlorambucil in therapeutic doses daily or courses of high-dose pulse therapy; extremely rarely – uncertainty when walking, tremors, muscle twitching, peripheral neuropathy, paresis, agitation, confusion, severe weakness, anxiety, hallucinations.
From the urinary system: extremely rarely – aseptic cystitis.
Others: drug hyperthermia, hyperuricemia or nephropathy due to increased production of uric acid (the result of rapid cell breakdown), menstrual irregularities, secondary amenorrhea, azoospermia, secondary malignancy.

Contraindications

Contraindications to the use of Leukeran are: pregnancy; lactation period; hypersensitivity to any component of this drug.
With caution (it is necessary to compare the risk and benefit) – inhibition of bone marrow function (pronounced leukopenia, thrombocytopenia and anemia); chickenpox (current or recent), herpes zoster, acute infectious diseases of a viral, fungal and bacterial nature, infiltration of bone marrow by tumor cells, gout (history), urate nephrourolithiasis, head trauma (history), epilepsy (history ), severe liver and kidney disease.

Storage conditions

Store Leukeran at a temperature of 2-8 ° C out of the reach of children. Shelf life is 3 years. Do not use the drug after the expiration date indicated on the package.